Gene expression profiling of histone deacetylase inhibition in epithelioid sarcoma

Epithelioid Sarcoma (ES) is a rare neoplasm uniquely comprised of cells exhibiting both mesenchymal and epithelial features. Having propensity for local and distant recurrence, it can pose a diagnostic dilemma secondary to pathologic complexity. Patients have dismal prognosis due to lack of effective therapy. HDAC inhibitors exhibit marked anti-tumor effects in various malignancies. Our studies demonstrate that pan-HDAC inhibitors constitute potentially novel therapeutics versus ES. Human ES cells (VAESBJ, HS-ES, Epi544) were studied in vitro to evaluate the effects of HDACi. Gene array analysis was used to identify the impact of HDACi on ES gene expression in three cell lines.

上皮样肉瘤（Epithelioid Sarcoma, ES）是一类罕见肿瘤，其独特性在于肿瘤细胞同时兼具间叶组织与上皮组织的特征。该肿瘤易发生局部与远处复发，且因病理结构复杂常引发诊断困境。由于缺乏有效治疗手段，患者预后极差。组蛋白去乙酰化酶抑制剂（HDAC inhibitors）在多种恶性肿瘤中展现出显著的抗肿瘤活性。本研究证实，广谱组蛋白去乙酰化酶抑制剂（pan-HDAC inhibitors）有望成为治疗ES的新型疗法。本研究通过体外实验对人ES细胞系（VAESBJ、HS-ES、Epi544）进行研究，以评估HDAC抑制剂的作用效果；并采用基因芯片分析技术，明确了HDAC抑制剂对三种细胞系中ES细胞基因表达的影响。